- Home
- CNTX vs IOBT Comparison
CNTX vs IOBT Comparison
Compare CNTX & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- IOBT
- Stock Information
- Founded
- CNTX 2015
- IOBT 2014
- Country
- CNTX United States
- IOBT Denmark
- Employees
- CNTX N/A
- IOBT N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- IOBT Health Care
- Exchange
- CNTX Nasdaq
- IOBT Nasdaq
- Market Cap
- CNTX 78.0M
- IOBT 91.6M
- IPO Year
- CNTX 2021
- IOBT 2021
- Fundamental
- Price
- CNTX $0.81
- IOBT $2.12
- Analyst Decision
- CNTX Strong Buy
- IOBT Strong Buy
- Analyst Count
- CNTX 5
- IOBT 3
- Target Price
- CNTX $5.50
- IOBT $9.33
- AVG Volume (30 Days)
- CNTX 193.2K
- IOBT 549.3K
- Earning Date
- CNTX 08-06-2025
- IOBT 08-12-2025
- Dividend Yield
- CNTX N/A
- IOBT N/A
- EPS Growth
- CNTX N/A
- IOBT N/A
- EPS
- CNTX N/A
- IOBT N/A
- Revenue
- CNTX N/A
- IOBT N/A
- Revenue This Year
- CNTX N/A
- IOBT N/A
- Revenue Next Year
- CNTX N/A
- IOBT N/A
- P/E Ratio
- CNTX N/A
- IOBT N/A
- Revenue Growth
- CNTX N/A
- IOBT N/A
- 52 Week Low
- CNTX $0.49
- IOBT $0.66
- 52 Week High
- CNTX $2.75
- IOBT $2.48
- Technical
- Relative Strength Index (RSI)
- CNTX 57.85
- IOBT 64.20
- Support Level
- CNTX $0.82
- IOBT $1.88
- Resistance Level
- CNTX $0.88
- IOBT $2.48
- Average True Range (ATR)
- CNTX 0.07
- IOBT 0.23
- MACD
- CNTX 0.00
- IOBT 0.03
- Stochastic Oscillator
- CNTX 42.87
- IOBT 68.60
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.